JNJ — Johnson & Johnson

Johnson & Johnson Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Worldwide Sales: $24.1 billion, up 6.4% operationally, despite a 540 basis point headwind from STELARA.
• Net Earnings: $5.2 billion; diluted EPS at $2.14, down from $4.54 year-over-year.
• Adjusted Net Earnings: $6.6 billion; adjusted diluted EPS at $2.70, a decrease of 1.4% and 2.5% respectively compared to Q1 2025.
• Innovative Medicine Sales: $15.4 billion, up 7.4% operationally, with significant contributions from oncology and immunology.
• MedTech Sales: $8.6 billion, up 4.6%, driven by growth in cardiovascular, surgery, and vision segments.

2. Strategic Updates and Business Highlights

• Innovative Medicine: Strong performance led by DARZALEX (sales of $4 billion, 18% growth) and TREMFYA (64% growth). New product launches include ICOTYDE, which is positioned as a first-line systemic therapy for psoriasis and has shown strong early uptake.
• MedTech: Continued growth in cardiovascular and surgical segments, with notable advancements in electrophysiology and the launch of new products like VARIPULSE Pro and the OTTAVA robotic surgical system.
• Pipeline Strength: 28 products generating over $1 billion in annual revenue, with ongoing FDA approvals and breakthrough designations for several therapies.
• Dividend Increase: The Board approved a 3.1% increase in the annual dividend to $5.36 per share, marking the 64th consecutive year of dividend growth.

3. Forward Guidance and Outlook

• Sales Guidance: Increased operational sales growth forecast to 5.9% to 6.9% for 2026, with a midpoint of $100.2 billion.
• Adjusted EPS Guidance: Raised by $0.02 to a range of $11.30 to $11.50, representing 5.7% growth at the midpoint.
• Long-term Growth: Confidence in achieving double-digit growth by the end of the decade, driven by new product launches and a strong pipeline.

4. Bad News, Challenges, or Points of Concern

• STELARA Decline: Experienced a significant 61.7% decline in sales due to biosimilar competition, impacting overall growth metrics.
• Margin Pressures: Declines in adjusted income margins for both Innovative Medicine and MedTech segments due to increased investment in new launches and unfavorable product mix.
• Market Competition: Competitive pressures in the MedTech space, particularly in the surgical and ophthalmology markets, with new entrants impacting sales growth.
• Economic Factors: Potential headwinds from economic conditions affecting healthcare spending and procedural volumes.

5. Notable Q&A Insights

• ICOTYDE Positioning: Strong early uptake with 1,500 prescriptions written shortly after launch; positioned as a first-line therapy for psoriasis, with ongoing discussions for broad reimbursement access.
• MedTech Market Sentiment: While facing competitive pressures, management expressed confidence in underlying demand and execution strategies, anticipating continued growth despite seasonal softness.
• Future Product Potential: Discussion on the potential of JNJ-4804 in IBD treatment paradigms and the importance of upcoming clinical trial results for future commercial discussions.
• INLEXZO Commercialization: Strong early performance post-J-code approval, with significant increases in patient insertions indicating robust market acceptance.

Overall, Johnson & Johnson's Q1 2026 results reflect a strong start to the year, driven by innovative product launches and a solid pipeline, while also facing challenges from competitive pressures and declining sales in certain segments. The company remains optimistic about its growth trajectory and strategic investments.